The GLP-1 phenomenon is making the fragmentation and dysfunction of the U.S. health care system even more apparent.
The Danish drugmaker Novo Nordisk argues that semaglutide, the active ingredient in Ozempic and Wegovy, are too complex for ...
Novo Nordisk (NVO) has asked the FDA to ban cheap copies of its weight loss drugs Wegovy and Ozempic, arguing they pose safety risks, ...
The medicines watchdog has revealed that almost 50 patients have been hospitalised “in association with glucagon-like peptide ...
Weight-loss jabs are not a quick fix for an “Instagram body”, the Health Secretary has warned. The medicines regulator has ...
Lilly will launch its Mounjaro obesity drug in Denmark next week, the U.S. drugmaker said on Thursday, bringing competition ...
Cedars-Sinai experts believe the study's findings can play a crucial role in developing healthcare policies that promote ...
Novo Nordisk's SOUL trial reveals a 14% reduction in major cardiovascular events with oral semaglutide in patients with type ...
Novo Nordisk , whose global profile has risen along with demand for its Wegovy weight-loss drug, is bolstering operations in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback